Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Champions Oncolog (CSBR)

Champions Oncolog (CSBR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Champions Oncolog One University Plaza Suite 307 Hackensack NJ 07601 USA

www.championsoncology.com P: 201-808-8400

Description:

Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc., engages in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company's Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments. This technology can evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents. Champions Oncology, Inc. is based in Baltimore, Maryland.

Key Statistics

Overview:

Market Capitalization, $K 69,737
Enterprise Value, $K 59,617
Shares Outstanding, K 13,594
Annual Sales, $ 53,870 K
Annual Net Income, $ -5,340 K
Last Quarter Sales, $ 12,020 K
Last Quarter Net Income, $ -2,530 K
EBIT, $ -8,800 K
EBITDA, $ -6,550 K
60-Month Beta 0.40
% of Insider Shareholders 45.69%
% of Institutional Shareholders 41.30%
Float, K 7,383
% Float 54.31%
Short Volume Ratio 0.63

Growth:

1-Year Return 1.79%
3-Year Return -49.41%
5-Year Return -40.76%
5-Year Revenue Growth 166.16%
5-Year Earnings Growth -178.57%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.19 on 03/12/24
Latest Earnings Date 03/20/24
Earnings Per Share ttm -0.72
EPS Growth vs. Prev Qtr -26.67%
EPS Growth vs. Prev Year -5.56%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-12 on 08/12/15

CSBR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -850.72%
Return-on-Assets % -32.62%
Profit Margin % -9.91%
Debt/Equity 0.00
Price/Sales 1.41
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.15
Interest Coverage -0.71
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar